Rigel Pharmaceuticals, Inc. (RIGL)
49.26
+0.54
(+1.11%)
USD |
NASDAQ |
Oct 09, 16:00
49.26
0.00 (0.00%)
After-Hours: 19:11
Rigel Pharmaceuticals Enterprise Value : 853.44M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 853.44M |
| October 07, 2026 | 839.82M |
| October 06, 2026 | 804.75M |
| October 05, 2026 | 836.09M |
| October 02, 2026 | 824.15M |
| October 01, 2026 | 820.79M |
| September 30, 2026 | 842.81M |
| September 29, 2026 | 856.61M |
| September 28, 2026 | 865.38M |
| September 25, 2026 | 843.37M |
| September 24, 2026 | 837.96M |
| September 23, 2026 | 842.43M |
| September 22, 2026 | 855.30M |
| September 21, 2026 | 823.03M |
| September 18, 2026 | 814.64M |
| September 17, 2026 | 799.90M |
| September 16, 2026 | 774.35M |
| September 15, 2026 | 772.11M |
| September 14, 2026 | 790.58M |
| September 11, 2026 | 825.83M |
| September 10, 2026 | 826.58M |
| September 09, 2026 | 825.46M |
| September 08, 2026 | 828.26M |
| September 04, 2026 | 852.51M |
| September 03, 2026 | 849.34M |
| Date | Value |
|---|---|
| September 02, 2026 | 866.50M |
| September 01, 2026 | 830.68M |
| August 31, 2026 | 806.06M |
| August 28, 2026 | 811.65M |
| August 27, 2026 | 818.74M |
| August 26, 2026 | 811.65M |
| August 25, 2026 | 816.69M |
| August 24, 2026 | 786.10M |
| August 21, 2026 | 800.65M |
| August 20, 2026 | 788.71M |
| August 19, 2026 | 820.61M |
| August 18, 2026 | 758.30M |
| August 17, 2026 | 736.48M |
| August 14, 2026 | 738.90M |
| August 13, 2026 | 705.51M |
| August 12, 2026 | 725.66M |
| August 11, 2026 | 728.46M |
| August 10, 2026 | 721.74M |
| August 07, 2026 | 693.95M |
| August 06, 2026 | 676.23M |
| August 05, 2026 | 699.73M |
| August 04, 2026 | 666.53M |
| August 03, 2026 | 642.84M |
| July 31, 2026 | 631.27M |
| July 30, 2026 | 654.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cytokinetics, Inc. | 8.706B |
| Ironwood Pharmaceuticals, Inc. | 957.22M |
| Capricor Therapeutics, Inc. | 318.56M |
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 17.29M |
| Revenue (Quarterly) | 78.70M |
| Total Expenses (Quarterly) | 61.41M |
| EPS Diluted (Quarterly) | 0.8835 |
| Gross Profit Margin (Quarterly) | 89.17% |
| Profit Margin (Quarterly) | 21.97% |
| Earnings Yield | 33.14% |
| Operating Earnings Yield | 9.04% |
| Normalized Earnings Yield | 33.15 |